study to evaluate the pharmacokinetics, pharmacodynamics, and safety of armodafinil in children and adolescents with excessive sleepiness associated with narcolepsy

Conditions: Narcolepsy

Summary: this study is to evaluate the pharmacokinetics, pharmacodynamics, and safety of single and multiple doses of armodafinil (50, 100, and 150 mg/day) in children and adolescents with excessive sleepiness associated with narcolepsy.


Eligibility criteria:
inclusion criteria: * written informed consent is obtained from each patient's parent or legal guardian and written assent is obtained from each patient. * the patient is a male or female 6 through 17 years of age with a body mass index (bmi) equal to or greater than 10th percentile for age and gender, inclusive. * the patient has a diagnosis of narcolepsy with cataplexy or narcolepsy without cataplexy according to the criteria established by the international classification of sleep disorders (icsd)-2 for narcolepsy. exclusion criteria: * the patient has any clinically significant uncontrolled medical condition (treated or untreated) other than narcolepsy. * the patient has a clinically significant deviation from normal in ecg, physical examination or vital sign findings, as determined by the investigator or medical monitor. * the patient is pregnant or lactating. (any patient becoming pregnant during the study will be withdrawn from the study) * the patient has any history of seizures, including febrile seizures, or a family history of seizures (in parents or siblings) which is not a consequence of trauma, stroke, or metabolic disturbance. * the patient has a history of head trauma associated with loss of consciousness. * the patient has current suicidal ideation, a history of a suicidal ideation, or a history of a suicide attempt. * the patient has a history of major depressive disorder, bipolar disorder, other significant mood disorders, schizophrenia and other psychotic disorders, eating disorders, or has a family history of suicide. * the patient has left ventricular hypertrophy or the patient has mitral valve prolapse and has experienced mitral valve prolapse syndrome. * the patient has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug. * the patient has used any monoamine oxidase inhibitors (maois) or stimulants within 14 days or 5 half-lives (whichever is longer) of the baseline visit. * the patient has used modafinil or armodafinil within 4 weeks of the baseline visit. * the patient has used an inducer of cyp3a4/5 within 28 days prior to study drug administration. * the patient has used an inhibitor of cyp3a4/5 within 14 days or 5 half lives (whichever is longer) prior to study drug administration. * the patient has a known sensitivity or idiosyncratic reaction to any compound present in modafinil or armodafinil, their related compounds, or to any metabolites or compound listed as being present in these medications. * the patient has a history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reactions * other criteria apply, please contact the investigator for additional information

Keywords: pediatric narcolepsy